Placental Stem Cell Therapy Market Size, Share, Trends, Growth, Consumption, Revenue, Company Analysis and Forecast 2022-2030

The global placental stem cell therapy market was valued at US$ 0.9 Bn in 2021 and is expected to reach US$ 4.7 billion by 2030 with a CAGR of 22% from 2022 to 2030.

Mesenchymal stem cells are emerging as powerful immunomodulators that are playing a key role in advancements made for the treatment of severe COVID-19 patients. MSC-based therapies hold future prospects for companies in the placental stem cell therapy market to create therapeutics for bronchopulmonary dysplasia (BPD) in infants born prematurely. MSCs have proven paracrine activity, which helps migrate toward inflamed sites and improves outcomes in patients suffering from neurological disorders. Ethical issues and immune mediated rejection of transplanted cells are posing as hurdles in the treatment of congenital metabolic diseases. Hence, companies should increase the production of human amniotic epithelial cells (hAECs) that are emerging as an alternative to hepatocyte transplantation (HT) for patients suffering from congenital metabolic diseases.

Key Findings

Robust Analytics and Independent Measurement Systems to Enrich Market Landscape: Players are keenly adopting technologies and techniques to ensure consistent quality of stem cells in order to expand the clinical applications of placental stem cell therapies. Extensive research on the characterization of placental stem cell therapies pivots on strides in biobanking technologies.

Rising Number of Allogeneic Stem Cell Transplantations Holds Promise for Regenerative Medicine: Growing utility of human amniotic/amnion epithelial cells (hAECs) in regenerative medicine has catalyzed significant investments in the placental stem cell therapy market over the past few years. Allogeneic hAECs are showing potential for leukemia and bronchopulmonary dysplasia (BPD) in various phases of clinical trials. The growing number of allogeneic stem cell transplantation procedures in developed nations has enriched the sales prospects in the placental stem cell therapy market.

MSC-based Cell Therapies Expand Prospects: Continued advances in cell-based therapies have engendered industry efforts in utilizing placental stem cell therapy for various diseases, expanding the sales prospects of the placental stem cell therapy market. These mainly include lung and liver injury, neurological disorders, acute kidney failure, and cardiovascular diseases. Especially in case of neurological disorders, mesenchymal stem/stromal cells (MSCs)-based cell therapy products are showing good therapeutic efficacy. For instance, allogeneic stem cell transplants have shown effectiveness in Alzheimer's disease in animal studies.

• In terms of application, the global placental stem cell therapy market has been divided into hematologic malignancies and disorders, congenital immunodeficiency disorders, metabolic disorders, neurological disorders, and others.
• The neurological disorders segment held a significant share of the global placental stem cell therapy market in 2021. Based on end user, the global placental stem cell therapy market has been split into hospitals & specialty clinics, clinical research organizations, and research institutes & academies.
• The clinical research organizations segment held a significant share of the global placental stem cell therapy market in 2021.

Ease of Procurement

• Placenta is a vascular organ with a known duration of life, and is only developed during the occurrence of pregnancy. It attaches to the uterine wall and the umbilical cord, which connects between the mother and the fetus, thereby supporting the growth and development of the fetus.
• Placenta plays an important role in transfer of gases, nutrients, and removal of waste products during pregnancy, which is vital for the sustenance of the fetus
• Placenta stem cells also provide additional benefit as compared to that offered by other tissues. These cells are easy to procure, with no harm to the mother or the baby. There are also no ethical issues associated with obtaining placenta, as it is considered a biological waste after birth.
• Placenta has high cell yield and is less exposed to infection, as it comes from an infection-naïve environment. This makes rendering any disease transmission less likely. This factor is considered a major driver of the placental stem cell therapy market.
• Rise in the number of storage banks and the awareness among people are key factors boosting the adoption of placental stem cell therapy

Prominent Regions

Asia Pacific held a major share of the global placental stem cell therapy market in 2019. Presence of key players and growth strategies adopted by these players are key factors driving the placental stem cell therapy market in the region. North America accounted for the second-largest share of the global placental stem cell therapy market in 2019. The expansion of the market in the region can be attributed to a well-developed healthcare sector. The placental stem cell therapy market in North America is likely to expand at a rapid pace during the forecast period. Technological developments in placental stem cell therapy is another major factor that is likely to propel the placental stem cell therapy market in the region.

Prominent players operating in the global placental stem cell therapy market include Lifebank Stem Cell Banking Celularity, Inc. Americord Registry ReeLabs Pvt. Ltd. Pluristem Therapeutics, Inc. Mesoblast Limited ReNeuron Group plc Athersys, Inc.

Market Segmentation

By Application

Hematologic Malignancies and Disorders

Congenital Immunodeficiency Disorders

Metabolic Disorders

Neurological Disorders

Others

By End User

Hospitals & Specialty Clinics

Clinical Research Organizations

Research Institutes & Academies

By Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Scope of the Report

VRR’s report on the global placental stem cell therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2020 to 2030. The report provides revenue of the global placental stem cell therapy market for the period 2018–2030, considering 2020 as the base year and 2030 as the forecast year.

The report also provides the compound annual growth rate (CAGR %) of the global placental stem cell therapy market from 2020 to 2030. The report has been prepared after an extensive primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the placental stem cell therapy market. Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the placental stem cell therapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global placental stem cell therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global placental stem cell therapy market. The report delves into the competition landscape of the global placental stem cell therapy market. Key players operating in the global placental stem cell therapy market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global placental stem cell therapy market profiled in this report.

Key Questions

What is the sales/revenue generated by the placental stem cell therapy market across all regions during the forecast period?

What are the opportunities in the global placental stem cell therapy market?

What are major drivers, restraints, opportunities, and threats in the market?

Which regional market is set to expand at the fastest CAGR during the forecast period?

Which drug class segment is expected to generate the highest revenue globally in 2030?

Which segment is projected to expand at the highest CAGR during the forecast period?

What are the market positions of different companies operating in the global market?

Research Objectives and Research Approach

The comprehensive report on the global placental stem cell therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of objectives behind this study, and key vendors and distributors operating in the market and regulatory scenario for approval of the products. For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global placental stem cell therapy market in terms of application, end user, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global placental stem cell therapy market.